Rick Stewart, Chief Executive Officer of Amarin, commented, "These findings are very encouraging and provide the validation to proceed with our clinical development program using EPA for Age Associated Memory Impairment and cognition. They are especially important as the findings reinforce the substantial body of pre-clinical work already undertaken. We expect to commence a clinical program in Age Associated Memory Impairment by year-end."
About the Role of EPA in Long-Term Potentiation (LTP), Age Associated Memory Impairment (AAMI) and Cognition
Aging is associated with impairment in LTP, resulting in Age Associated Memory Impairment (AAMI) and cognitive function. This impairment results from inflammatory and oxidative changes in the hippocampal area of the brain. In pre-clinical studies, analysis of the mechanisms underlying the effect of aging on hippocampal function has focused to a significant extent on analysis of age-related changes in long-term potentiation (LTP) in the hippocampus.
Further, these findings support the substantial preclinical studies previously published in the use of EPA to promote LTP in aging models.
Amarin is committed to improving the lives of patients suffering from diseases of the central nervous system. Our goal is to be a leader in the research, development and commercialization of novel drugs that address unmet patient needs.
Amarin's core development pipeline includes programs for Parkinson's disease, Age Associated Memory Impairment, cognition, epilepsy seizures and other Central Nervous System (CNS) disorders.
Amarin has its primary stock market listing in the U.S. on NASDAQ ("AMRN") and secondary listings in the U.K. and Ireland on AIM ("AMRN") and IEX ("H2E"), respectively.
For press releases a
|SOURCE Amarin Corporation Plc|
Copyright©2007 PR Newswire.
All rights reserved